China Shenghuo to Resume Trading on NYSE Alternext US LLC
Pharmaceutical Holdings, Inc. (NYSE Alternext US: KUN) (“China Shenghuo” or
the “Company”), today announced that the Company’s shares would resume trading
on NYSE Alternext US LLC (“NYSE Alternext US” or the “Exchange”) at the open
of business on
trade under the symbol “KUN.”
“We are delighted that the Exchange has decided to allow our shares to
resume trading,” said Mr. Gui Hua Lan, Chief Executive Officer of China
Shenghuo. “The relisting of our shares marks a major milestone for the Company
and it offers a measure of reassurance to both our retail and institutional
investors that we have succeeded in putting a very challenging period in the
Company’s history behind us.”
About China Shenghuo
Founded in 1995, China Shenghuo is a specialty pharmaceutical company that
focuses on the research, development, manufacture and marketing of Sanchi-
based medicinal and pharmaceutical, nutritional supplement and cosmetic
products. Through its subsidiary, Kunming Shenghuo Pharmaceutical (Group) Co.,
Ltd., it owns thirty SFDA (State Food and Drug Administration) approved
medicines, including the flagship product Xuesaitong Soft Capsules, which has
already been listed in the Insurance Catalogue. At present, China Shenghuo
incorporates a sales network of agencies and representatives throughout
which markets Sanchi-based traditional Chinese medicine to hospitals and drug
stores as prescription and OTC drugs primarily for the treatment of
cardiovascular, cerebrovascular and peptic ulcer disease. The Company also
exports medicinal products to Asian countries such as
Safe Harbor Statement
This press release may contain certain “forward-looking statements,” as
defined in
that involve a number of risks and uncertainties. There can be no assurance
that such statements will prove to be accurate, and the actual results and
future events could differ materially from management’s current expectations.
Such factors include, but are not limited to, risks of litigation and
governmental or other regulatory inquiry or proceedings arising out of or
related to any of the matters described in recent press releases, including
arising out of the restatement of the Company’s financial statements; the
Company’s continuing ability to satisfy any requirements which may be
prescribed by the Exchange for continued listing on the Exchange; potential
adverse effects to the Company’s financial condition, results of operations or
prospects as a result of possible changes to or restatements of prior period
financial statements; risks arising from potential weaknesses or deficiencies
in the Company’s internal control over financial reporting; the Company’s
reliance on one supplier for Sanchi; the possible effect of adverse publicity
on the Company’s business, including possible contract cancellation; the
Company’s ability to develop and market new products; the Company’s ability to
establish and maintain a strong brand; the Company’s continued ability to
obtain and maintain all certificates, permits and licenses required to open
and operate retail specialty counters to offer its cosmetic products and
conduct business in
rights; market acceptance of the Company’s products; changes in the laws of
the Company of complying with current and future governmental regulations; the
impact of any changes in governmental regulations on the Company’s operations;
general economic conditions; and other factors detailed from time to time in
the Company’s filings with the United States Securities and Exchange
Commission and other regulatory authorities. The Company undertakes no
obligation to publicly update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise.
For more information, please contact:
China Shenghuo Pharmaceutical Holdings, Inc.
Mr. Changhua Mu
Securities Affairs Representative
Tel: +86-871-728-2698
Email: c.mu@chinashenghuo.net
Grayling Global
Eddie Cheung
Investor Relations
Tel: +1-646-284-9414
Email: echeung@hfgcg.com
SOURCE China Shenghuo Pharmaceutical Holdings, Inc.